Modern management of acute myocardial infarction is built on a clinical evidence base
drawn from many studies undertaken over the past three decades. The evolution in clinical …

This article discusses the perioperative management of antithrombotic therapy and is part of
the American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th …

Background Treatment with the direct thrombin inhibitor bivalirudin, as compared with
heparin plus glycoprotein IIb/IIIa inhibitors, results in similar suppression of ischemia while …

Background: Bleeding and transfusion after percutaneous coronary intervention (PCI) are
known predictors of mortality. Transradial arterial access reduces bleeding and transfusion …

Objectives: The aim of the study was to investigate the relationship between bleeding within
the 30 days after percutaneous coronary interventions (PCI) and 1-year mortality and to …

OBJECTIVE: Many recommendations for aspirin in stable cardiovascular disease are based
on analyses of all antiplatelet therapies at all dosages and in both stable and unstable …

Background Despite advances in the management of deep vein thrombosis (DVT) and
pulmonary embolism (PE), relatively few contemporary data describe and compare …

This chapter about antithrombotic therapy for coronary artery disease is part of the
Antithrombotic and Thrombolytic Therapy: American College of Chest Physicans Evidence …

In patients undergoing coronary stenting, long-term dual antiplatelet therapy with aspirin and
clopidogrel reduces atherothrombotic events but also increases the risk of bleeding. The …

BACKGROUND: Antiplatelet therapy with clopidogrel and acetylsalicylic acid (ASA) reduces
major cardiovascular events in patients with ST and non–ST-segment-elevation acute …